In this video filmed at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024), Hagop Kantarjian,MD, professor and chair in the Department of Leukemia at the University of Texas MD Anderson Cancer Center, speaks with Mark R. Litzow, MD, at the Mayo Clinic in Rochester, Minnesota, on the phase 3 study E1910.

The study investigated the addition of blinatumomab to consolidation chemotherapy in adult patients with B-cell precursor acute lymphoblastic leukemia in MRD-negative remission. Interim results from the phase 3 trial were published in the New England Journal of Medicine in July 2024.

Of the study’s results, Dr. Litzow said, “We felt that this represents a new standard of care to add blinatumomab to the treatment of patients in MRD-negative remission, leading the Food and Drug Administration to approve blinatumomab for use in consolidation therapy in June of this year.”

To become a SOHO member, visit http://soho.click/join.